Chiappori, Alberto

Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 4,593

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment

Cited by 2,798

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

Shaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 638

Combination of p53 Cancer Vaccine with Chemotherapy in Patients with Extensive Stage Small Cell Lung Cancer

Antonia, S. J., Mirza, N., Fricke, I., Chiappori, A., Thompson, P., Williams, N., Bepler, G., Simon, G., Janssen, W., Lee, J.-H., et al. (2006) · Clinical Cancer Research

Immunotherapy and Immune ResponsesLung Cancer Research Studies

Cited by 444

Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer

Pietanza, M. C., Waqar, S. N., Krug, L. M., Dowlati, A., Hann, C. L., Chiappori, A., Owonikoko, T. K., Woo, K. M., Cardnell, R. J., Fujimoto, J., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Research StudiesPARP inhibition in cancer therapy

Cited by 399

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J., & Gabrilovich, D. I. (2010) · Expert Opinion on Biological Therapy

Immunotherapy and Immune ResponsesLung Cancer Research Studies

Cited by 126

Variance of SUVs for FDG-PET/CT is Greater in Clinical Practice Than Under Ideal Study Settings

Kumar, V., Nath, K., Berman, C. G., Kim, J., Tanvetyanon, T., Chiappori, A. A., Gatenby, R. A., Gillies, R. J., & Eikman, E. A. (2013) · Clinical Nuclear Medicine

Medical Imaging Techniques and ApplicationsRadiomics and Machine Learning in Medical Imaging

Cited by 76

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer

Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy

Immunotherapy and Immune ResponsesLung Cancer Research Studies

Cited by 64

Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms.

Tafreshi, N. K., Pandya, D. N., Tichacek, C. J., Budzevich, M. M., Wang, Z., Reff, J. N., Engelman, R. W., Boulware, D. C., Chiappori, A. A., Strosberg, J. R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging

Radiopharmaceutical Chemistry and ApplicationsNeuroendocrine Tumor Research Advances

Cited by 50

A phase II clinical trial of the CDK 4/6 inhibitor palbociclib (PD 0332991) in previously treated, advanced non-small cell lung cancer (NSCLC) patients with inactivated CDKN2A.

Gopalan, P. K., Pinder, M. C., Chiappori, A., Ivey, A. M., Gordillo Villegas, A., & Kaye, F. J. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies

Cited by 47